Multidisciplinary Treatment for GIST

Video

Gastrointestinal stromal tumors (GISTs) are relatively rare, requiring a comprehensive knowledge base of various experts in order to provide patients with the best possible care, comments Syma Iqbal, MD. The multidisciplinary approach should include gastroenterologists who are experienced in identifying these tumors, radiologists who are skilled in assessing the density of the lesions on the scans, pathologists who are savvy at knowing what markers to look for, and surgeons who are familiar with surgical techniques used to remove these tumors.

The response rate to the tyrosine kinase inhibitor imatinib for patients with advanced or unresectable GIST is approximately 50%, states Iqbal. Imatinib can be administered in patients who are ineligible for surgical resection in order to shrink the tumor enough so that surgery becomes possible.

There is no clear data regarding the optimal duration of neoadjuvant imatinib, explains Iqbal, noting that patients tend to have responses anywhere from 6 to 12 months following treatment initiation. Tumors may continue to shrink beyond this time point. General guidelines recommend intervening when the patient becomes surgically resectable rather than waiting for maximum response.

Related Videos
In this fifth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.
In this fourth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss research efforts being made with organoids to address existing questions with immunotherapy and the exploration of multimodality approaches to improve outcomes.
In this third episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential benefits of utilizing immunotherapy approaches earlier on in the disease course.
In this second episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, explain the challenges faced with preventing or detecting these cancers early and the understanding that is needed to develop effective early detection methods and move the needle forward.
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Joachim G. J. V. Aerts, MD, PhD
Nathaniel Myall, MD
Martin Cannon, PhD, professor, Department of Microbiology, University of Arkansas for Medical Sciences College of Medicine
Pedro Barata, MD, MSc
In this fourth episode of OncChats: Examining LIFU–Aided Liquid Biopsy in Glioblastoma, Manmeet Singh Ahluwalia, MD, and Michael W. McDermott, MD, discuss the key objectives of the phase 3 LIMITLESS study (NCT05317858) examining low-intensity focused ultrasound with immunotherapy and chemotherapy in patients with lung cancer and brain metastases.
Related Content
Hesham Abdullah, MD

Dostarlimab/Chemo Receives FDA Priority Review for Expanded Indication in Endometrial Cancer

April 24th 2024
Article
Marvels in Medicine: Allison Talks Everything from Advances in Immunotherapy to Jamming With Willie Nelson

Marvels in Medicine: Allison Talks Everything from Advances in Immunotherapy to Jamming With Willie Nelson

November 22nd 2021
Podcast
Elizabeth Plimack, MD, MS, FASCO

Immunotherapy-Based Approaches Make Waves in Bladder Cancer

April 17th 2024
Article
Dietrich Details Data and Future Research With Immunotherapy in Stage III NSCLC

Dietrich Details Data and Future Research With Immunotherapy in Stage III NSCLC

September 20th 2021
Podcast
Matthew Galsky, MD

Adjuvant Nivolumab Provides Sustained DFS Benefit, Favors OS in Muscle-Invasive Urothelial Cancer

April 16th 2024
Article
Do-Youn Oh, MD, PhD, professor, Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine

Durvalumab Plus Chemo Sustains 3-Year OS Benefit in Advanced Biliary Tract Cancer

April 16th 2024
Article